

## **Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike**

Andrew R. Crowley<sup>1\*</sup>, Harini Natarajan<sup>1\*</sup>, Andrew P. Hederman<sup>2</sup>, Carly A. Bobak<sup>3</sup>, Joshua A. Weiner<sup>2</sup>, Wendy Wieland-Alter<sup>4</sup>, Jiwon Lee<sup>2</sup>, Evan M. Bloch<sup>5</sup>, Aaron A.R. Tobian<sup>5</sup>, Andrew D. Redd<sup>6,7</sup>, Joel N. Blankson<sup>6</sup>, Dana Wolf<sup>8</sup>, Tessa Goetghebuer<sup>9,10</sup>, Arnaud Marchant<sup>9</sup>, Ruth I. Connor<sup>4</sup>, Peter F. Wright<sup>4</sup>, Margaret E. Ackerman<sup>1,2,3,#</sup>

<sup>1</sup>Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA

<sup>2</sup>Thayer School of Engineering, Dartmouth College, Hanover, NH, USA

<sup>3</sup>Biomedical Data Science, Dartmouth College, Hanover, NH, USA

<sup>4</sup>Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

<sup>5</sup>Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA

<sup>6</sup>Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA

<sup>7</sup>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

<sup>8</sup>Hadassah University Medical Center, Jerusalem, Israel

<sup>9</sup>Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium

<sup>10</sup>Pediatric Department, CHU St Pierre, Brussels, Belgium

\*Contributed equally

# Corresponding Author

Margaret E. Ackerman  
14 Engineering Drive  
Hanover, NH 03755  
[margaret.e.ackerman@dartmouth.edu](mailto:margaret.e.ackerman@dartmouth.edu)  
(ph) 603 646 9922  
(fax) 603 646 3856

## Abstract

Pre-existing antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2 have the potential to influence the antibody response to COVID-19 vaccination and infection for better or worse. In this observational study of mucosal and systemic humoral immunity in acutely infected, convalescent, and vaccinated subjects, we tested for cross reactivity against endemic CoV spike (S) protein at subdomain resolution. Elevated responses, particularly to the  $\beta$ -CoV OC43, were observed in all natural infection cohorts tested and were correlated with the response to SARS-CoV-2. The kinetics of this response and isotypes involved suggest that infection boosts preexisting antibody lineages raised against prior endemic CoV exposure that cross react. While further research is needed to discern whether this recalled response is desirable or detrimental, the boosted antibodies principally targeted the better conserved S2 subdomain of the viral spike and were not associated with neutralization activity. In contrast, vaccination with a stabilized spike mRNA vaccine did not robustly boost cross-reactive antibodies, suggesting differing antigenicity and immunogenicity. In sum, this study provides evidence that antibodies targeting endemic CoV are robustly boosted in response to SARS-CoV-2 infection but not to vaccination with stabilized S, and that depending on conformation or other factors, the S2 subdomain of the spike protein triggers a rapidly recalled, IgG-dominated response that lacks neutralization activity.

## Introduction

The ongoing pandemic of SARS-CoV-2 represents the third time in just two decades that a novel coronavirus (CoV) with significant morbidity and mortality has begun to circulate among humans<sup>1</sup>. Given the alarming frequency of these occurrences, the COVID-19 pandemic serves as a call to action to safeguard against continued emergence of novel human CoV. Unlike in the earlier outbreaks of SARS-CoV and MERS-CoV, however, SARS-CoV-2 has proven to be highly transmissible, infecting a substantial portion of the global population – a conservative estimate of the prevalence of infection based on only confirmed cases corresponds to over 2%<sup>2</sup>, while estimates of the total figure in the United States exceed 16% of the population<sup>3</sup>. The extent to which the immune responses generated by these and other endemic CoV exposures might serve as an effective deterrent against the emergence of novel CoV strains remains an open question.

Insights into the effect of exposure to endemic CoVs in the years leading up to the COVID-19 pandemic could suggest whether preexisting antibodies are likely to contribute beneficially or detrimentally to outcomes of infection by a novel strain. Under the hypothesis of original antigenic sin, preexisting humoral memory imprinted from prior exposure to related antigens partially predestines the antibody repertoire to focus on the epitopes of a new threat that closely resemble those for which there is an existing solution. Because neutralizing epitopes are subject to additional selective pressure, this recall and re-diversification of existing antibody lineages may hinder the immune system's ability to generate effective neutralizing antibodies<sup>4</sup>. This phenomenon has been most convincingly established in the context of influenza virus infection, with support from both well-controlled animal model experiments<sup>4,5</sup> and observational studies of human natural infection histories<sup>6-10</sup>. Similar observations have been made in the context of diverse dengue virus serotypes<sup>11</sup>. These and other studies have shown despite being a key hallmark of effective long-term immune defense, anamnestic responses are not without potential downsides.

Antibody-dependent enhancement (ADE), a phenomenon by which cross-reactive antibodies induced by a prior exposure to a related pathogen promote infection of cell types bearing antibody Fc receptors and potentially elevate morbidity and mortality (reviewed in<sup>12,13</sup>), suggests further potential advantages of a humoral blank slate. Though observed *in vitro*<sup>14,15</sup>, there has not been abundant evidence for the biological relevance of classical ADE in the context of SARS-CoV-2 *in vivo*<sup>15,16</sup>. Nonetheless, the role of non-neutralizing antibodies resulting from cross-strain challenges in promoting ADE in cases of dengue fever<sup>17</sup> has motivated concern about COVID-19 enhancement<sup>18-20</sup>.

The extent to which preexisting responses to prior endemic CoV exposures may influence responses to SARS-CoV-2 infection and vaccination is not yet clear, but has been suggested from studies relating recent endemic CoV infection with reduced severity of COVID-19<sup>21,22</sup>. Numerous studies have observed elevated responses to endemic CoV following SARS-CoV-2 infection<sup>23-27</sup>, and more recent work has shown that the magnitude of this “back-boosting” effect is inversely correlated with the induction of IgG and IgM against to SARS-CoV-2 spike (S) protein<sup>28</sup>. Given differential degrees of homology between the receptor binding domain (RBD) in S1 that is the target of the majority of neutralizing antibodies, and the better conserved S2 domain that may be the target of antibodies with diverse effector functions but which are rarely neutralizing, the original antigenic sin hypothesis suggests that lower titers of neutralizing antibodies against SARS-CoV-2 may result from boosting of pre-existing cross-reactive lineages. Here, this apparent boosting effect is evaluated in diverse cohorts with the goal of beginning to understand its implications.

## Results

### *Structural Analysis of SARS-CoV-2*

Sequence conservation across the human CoV spike protein is not uniformly distributed: the N-terminal domain (NTD) of SARS-CoV-2 that contains the RBD responsible for interacting with human angiotensin-converting enzyme 2 (ACE2) and initiating viral entry has lower homology to the corresponding subdomains of other CoVs than do the S2 subdomains where the fusion peptide, heptad repeat, and central helix required for fusion are located (**Figure 1A**). In contrast to the S2 domain, structural comparison of various subdomains of the SARS-CoV-2 S protein show that both the NTD and RBD of the spike protein are poorly conserved across CoV (**Figure 1B**). Superimposition of the SARS CoV-2 S1 and S2 domains with the most well conserved widely circulating endemic human CoV, OC43, show high structural conservation in S2 and the NTD, and a complete lack of homology in the RBD that is consistent with the differing entry receptors used by these  $\beta$ -CoV (**Figure 1C, Supplemental Figure 1**). Based on both structural and sequence homology, it stands to reason that preexisting antibodies raised against endemic human CoV are more likely to target the better conserved regions of SARS-CoV-2 such as S2, and less likely to recognize the RBD<sup>29,30</sup>.

### *Subject Cohorts*

A diversity of cohorts were evaluated in this observational study (**Table 1**). Subjects naturally infected with SARS-CoV-2 comprised a small cohort of convalescent subjects for which serum and mucosal samples were available, a larger cohort of convalescent plasma donors, acutely infected individuals, pregnant women infected in their third trimester, and a small set of subjects for whom pre- and post-infection samples were available. Subjects vaccinated against SARS-CoV-2 with mRNA included cohorts of healthy adults, and pregnant women vaccinated in their third trimester. Samples were analyzed alongside samples from naïve (n = 15) and historical (n = 38) negative controls.

### *Elevated Responses to Endemic CoV in Serum, Nasal Wash, and Stool Among SARS-CoV-2 Infected Subjects*

The magnitude and specificity of IgM, IgA, and IgG responses were determined across a panel of SARS-CoV-2 and endemic CoV antigens (**Supplemental Table 2**) in two previously described cohorts of convalescent subjects<sup>31,32</sup> (**Table 1**). In the smaller (DHMC, n = 26) cohort, mucosal samples were available, and responses in nasal wash and stool were also defined. Relative to SARS-CoV-2 naïve controls, elevated serum IgA and IgG, but not IgM responses to whole S of diverse endemic CoV were frequently observed (**Figure 2**). Among endemic CoV, elevated levels of OC43-specific responses in serum were most pronounced, but were largely restricted to the S2 domain and whole unstabilized S. Similarly, elevated IgG responses to other endemic CoV were observed in serum from convalescent subjects to the spike proteins of endemic CoV, but not to the S1 domain alone. Indeed, elevated serum responses specific to the S1 domain of these CoV were not observed for any antibody isotype or subclass (**Figure 2B, Supplemental Figure 2**).

These observations were validated in a larger (JHMI, n = 126) cohort of convalescent plasma donors: elevated levels of IgG and IgA, but not IgM, to diverse endemic CoV were observed in plasma (Figure 2B, **Supplemental Figure 3**). Elevated responses were most pronounced for  $\beta$ -CoV (OC43 and HKU1) but were present for  $\alpha$ -CoV as well. The absence of elevated IgM responses among convalescent subjects is consistent with recall of class-switched antibodies as opposed to the *de novo* elicitation of cross-reactive antibodies. Additionally, differential reactivity profiles were observed across three different OC43 antigens: proline-stabilized OC43 S (S-2P), OC43 S, and OC43 S2. Whereas elevated responses to OC43 S-2P among convalescent subjects in either cohort were not observed compared to naïve controls,

responses to both OC43 S and OC43 S2 (available only for the smaller cohort) were observed for IgG, but not IgM (**Supplemental Figure 4**).

This effect was not limited to serum; elevation of endemic CoV antibody responses was also observed in nasopharyngeal wash samples (**Figure 2A,B, Supplemental Figure 2**) and stool (**Supplemental Figure 2**). Again, these elevated responses were restricted to IgG and/or IgA isotypes, consistent with cross-reactive antibodies being boosted in a recall response during SARS-CoV-2 infection, and were observed for whole S or the S2 domain, but not S1.

#### *OC43-Specific Antibody Responses in Acute infection*

To better explore the kinetics of these responses, antibodies were measured in serum collected from a cohort of acutely infected subjects ( $n = 10$ , **Table 1**) two weeks after a positive PCR diagnosis afforded by twice weekly surveillance. At this early timepoint, subjects appeared to have robustly elevated levels of CoV-2 unstabilized S-specific IgG compared to naïve controls (**Figure 3A**). Again, these responses were observed for whole unstabilized S and the S2 domain, but not for the pre-fusion conformation stabilized S-2P form of OC43 spike. In contrast, only a minor increase in IgM recognizing unstabilized OC43 S was observed (<2-fold) (**Figure 3A**). Though cross-sectional in nature and reliant on a small number of subjects, these isotype profiles in acute infection nonetheless further suggest a recalled rather than novel response against the relevant cross-reactive epitopes in S2 and unstabilized spike, presumably in the post-fusion conformation.

In an effort to resolve whether elevated responses to endemic  $\beta$ -CoV were driven by boosting of pre-existing cross-reactive antibody lineages, a small cohort of subjects ( $n = 3$ ) for which pre- and post-SARS-CoV-2 infection serum samples were available was analyzed (**Table 1**). The median increase in OC43 S2-specific IgA and IgG were 3.7- and 20-fold, respectively, between the pre- and post-infection timepoints (**Figure 3B**). In contrast, the median change in OC43 S2-specific IgM was within 2-fold, providing further support that the elevated responses to endemic  $\beta$ -CoV are due to boosting of pre-existing cross-reactive antibodies originally raised against homologous epitopes found in endemic CoV. Like in other convalescent subject cohorts, this boosting effect was observed in response to OC43 S and S2, but not the pre-fusion conformation stabilized S-2P form of OC43, which showed a median change less than 1.1-fold across isotypes. Boosting of IgG responses specific to the full-length spike of another endemic  $\beta$ -CoV, HKU1, was also observed. IgG and IgA but not IgM responses to whole unstabilized S, but not the S1 domain, of HKU1 were elevated following SARS-CoV-2 infection (**Figure 3B, Supplemental Figure 5**). Collectively, these results further suggest that recalled cross-reactive

antibodies may be more likely to recognize both the better conserved S2 domain and post- rather than pre-fusion conformations of spike.

#### *Correlations Between Antibody Responses to OC43 and SARS-CoV-2*

We next examined correlative relationships between SARS-CoV-2- and OC43-specific IgG responses in convalescent cohorts. Whereas the magnitude of IgG responses to CoV-2 S2 were well correlated to those binding unstabilized OC43 S ( $R_P = 0.61$ ) and its S2 domain ( $R_P = 0.45$ ), they were less well correlated to responses to stabilized OC43 S-2P ( $R_P = 0.29$ ) (**Figure 4A**). Expanding this analysis to include additional CoV-2 specificities and other isotypes showed a hierarchy of correlative relationships (**Figure 4B, Supplemental Figure 6**). CoV-2-specific responses were better correlated to OC43 responses specific for unstabilized rather than stabilized spike. IgG responses showed stronger relationships than did IgA, which were in turn stronger than IgM. Consistent with the lack of elevated IgM to endemic CoV, these measures only rarely showed a statistically significant relationship with CoV-2-specific IgM responses. Lastly, among CoV-2 antigens tested, correlations with OC43 responses were strongest for the S2 domain and whole spike (S-2P), and weaker or absent for S1 and the RBD. Collectively, these correlative relationships are consistent with recall of class-switched antibodies recognizing shared epitopes in the S2 domain from prior endemic CoV exposure induced by SARS-CoV-2 infection.

#### *Direct Evidence of Molecular Cross-Reactivity of SARS-CoV-2 and OC43-Specific Antibodies*

To date, antibody cross-reactivity has been inferred from indirect evidence in the form of boosted responses to endemic CoV<sup>23-27</sup>, and more conclusively observed for select monoclonal antibodies that have been cloned and cross tested<sup>33,34</sup>. To better generalize the more definitive monoclonal studies, we sought to directly define the cross-reactivity of polyclonal antibodies raised following SARS-CoV-2 infection. Antibodies specific to stabilized CoV-2 S-2P, RBD, and S2 and unstabilized OC43 S were selectively purified from serum samples from 30 SARS-CoV-2-infected subjects with a range of disease severity and humoral response profiles. Unfractionated and antigen-specific antibodies eluted from affinity purification matrices presenting various epitopes of the CoV-2 spike protein and OC43 were then characterized to determine their cross-reactivity and isotype profiles. Successful affinity purification was confirmed by comparison of antigen-specific binding signal relative to total Ig levels for each isotype (**Figure 5A, Supplemental Figures 7-18**). While relative binding signal was elevated for each targeted antigen, it was not observed for control antigens such as influenza hemagglutinin (HA) (**Figure 5A**) or tetanus toxoid (**Supplemental Figures 7-18**).

A number of interesting differences in cross-reactivity for antibodies with differing isotypes and antigen-specificities were apparent. For example, OC43 S-specific fractions showed elevated recognition of CoV-2 S2 and S-2P, but not RBD (**Figure 5A**), demonstrating molecular cross-reactivity as a general feature of polyclonal IgG responses in convalescent subjects. Additionally, IgG in the CoV-2 S2-specific fractions cross-reacted robustly with OC43 S, but no cross-reactivity in the IgM fraction was observed, despite a robust IgM response to CoV-2 S2 (**Figure 5B**), suggesting that while SARS-CoV-2 infection elicits IgM responses to the S2 domain, these presumed *de novo* responses are not cross-reactive to OC43.

To begin to define the functional significance of these cross-reactive antibodies, eluted fractions were pooled and tested for neutralization potency. Whereas purified CoV-2 RBD and S-2P-specific fractions induced robust neutralization, neither purified OC43 S-specific nor SARS-CoV-2 S2 domain-specific serum antibodies had detectable neutralization activity (**Figure 5C**).

To quantify the extent of cross-reactivity across antigens and isotypes, the unfractionated and affinity purified fractions from each subject were titrated, and enrichment of antigen-specific antibodies was computed by calculating the difference between the area under the curve (AUC) for the best fit lines calculated from data points across subjects for each antibody specificity and each isotype in eluates versus unfractionated samples (**Figure 6**).

IgM, IgA, and IgG antibodies purified based on binding to SARS-CoV-2 RBD cross reacted with proline-stabilized spike (S-2P and S-6P) and, to a lesser extent, unstabilized S, but showed no evidence of cross-reactivity to SARS-CoV-2 S2 or to endemic CoV (**Figure 6A**). Because the overwhelming majority of neutralizing antibodies target the RBD, these results suggest that RBD-specific antibody responses raised by natural infection are unlikely to exhibit exceptionally broad CoV neutralization activity. Indeed, SARS-CoV-2 RBD-specific antibodies showed low, albeit detectable cross-reactivity toward even SARS-CoV S and S1.

Similarly, across all isotypes, antibody pools purified based on binding to stabilized SARS-CoV-2 S-2P showed the expected cross-reactivity to SARS-CoV-2 RBD, S2, unstabilized S, and stabilized S with six proline substitutions (S-6P) (**Figure 6B**). However, while both IgA and IgG components of SARS-CoV-2 S-2P-specific serum antibody fractions showed binding to OC43, cross-reactive IgM was not evident. Similarly, IgA and IgG, but not IgM, specific for SARS-CoV-2 S2 bound as expected to SARS-CoV-2 proteins as well as OC43, SARS-CoV, MERS, and other endemic CoV S2 domains (**Figure 6C**).

Lastly, OC43 S-specific antibodies were similarly purified and profiled for cross-reactivity. Despite the presumption that subjects had not experienced OC43 infection recently, IgM, IgA, and IgG to OC43 S were all successfully enriched (**Figure 6D**). IgA and IgM fractions showed



cross-reactivity to a broad array of endemic CoV S but not S1 proteins. Likewise, OC43-specific IgA and IgG antibodies showed cross-reactivity to SARS-CoV-2 proteins containing the S2 domain. In contrast, OC43 S-specific IgM antibodies showed elevated recognition of diverse pandemic, pathogenic, and endemic S proteins in unstabilized forms, but a lack of recognition of stabilized prefusion conformations of CoV-2 spike, or the S1 domains of most other CoV tested. Given binding to whole S but not the S1 domain, this recognition is presumably principally driven via recognition of S2.

### *Immunization With Stabilized Spike Changes Cross-Reactivity Profiles*

Based on the differential ability of affinity-purified antibodies to recognize stabilized and unstabilized forms of CoV spike proteins, we next sought to determine whether responses to natural infection differ from those that result from mRNA vaccination with stabilized SARS-CoV-2 spike (S-2P). To investigate this possibility, antibody responses were analyzed in two cohorts of pregnant women (**Table 1**) who were either infected (n = 38) or vaccinated (n = 50) during their third trimester, as well as a validation cohort of healthy vaccinated subjects (n = 37). Fascinatingly, despite inducing considerably greater levels of SARS-CoV-2-specific antibodies, immunization with stabilized spike (S-2P) failed to result in elevated IgG responses to endemic CoV among pregnant women (**Figure 7**). Similarly, elevated levels of OC43-reactive IgA responses were not observed among vaccinated mothers, and neither infected nor vaccinated mothers showed elevated levels of OC43-reactive IgM (**Supplemental Figure 19**). These differing immunogenicity profiles suggest that the presentation of native spike in the context of natural infection and stabilized spike in the context of mRNA vaccination are distinct. Lastly, to confirm this observation, responses, a validation cohort of mRNA-vaccinated healthy adults was evaluated (**Table 1**). In this cohort, while IgG responses to OC43 were statistically significantly elevated for S and S2 antigens, the effect was small (<2.5-fold) (**Figure 7**); elevated IgA or IgM responses were not observed (**Supplemental Figure 19**).

In sum, elevated IgA and IgG but not IgM responses to the endemic CoV OC43 were observed in five distinct cohorts, including acutely infected, cross-sectional, and longitudinal convalescent cohorts. In contrast, two cohorts of subjects immunized with stabilized spike in the form of mRNA-based vaccines showed no (IgA and IgM) or only a small (IgG only, and in only one cohort) elevation of binding to endemic CoV OC43. In combination with the lack of boosting of responses that cross-react with endemic CoV, the high levels of neutralization activity observed to result from vaccination<sup>35</sup> suggest favorable antigenicity of the pre-fusion conformation of S, and that the costs of original antigenic sin might be avoided by immunogen design.

## Discussion

Cross-reactivity of endemic CoV antibodies against SARS-CoV-2 is of potential clinical relevance. The original antigenic sin hypothesis suggests that pre-existing immunity results in the reactivation of a response to an earlier strain, as opposed to the formation of an unbiased response against the current strain. While this recall could offer temporal advantages, it may reduce the formation of neutralizing antibodies thereby dampening effective clearance of the novel virus. Seminal studies of responses to influenza, based on epidemiology, modeling, and repertoire profiling suggest that the antibodies generated from childhood exposure to influenza are 'imprinted' and exert a major influence on the nature of the antibody response elicited upon subsequent exposures in humans<sup>6-10</sup>. It has been suggested that this phenomenon may exist in SARS-CoV-2 infection<sup>28</sup>.

To better understand the role that prior exposure to CoV plays in antibody responses to SARS-CoV-2, we examined antigen-specific antibody responses against endemic and pandemic human CoV in subjects one month after SARS-CoV-2 infection. We measured heightened OC43-specific responses in SARS-CoV-2 convalescent subjects when compared to naïve controls and observed that the magnitude of these responses correlated with responses to SARS-CoV-2 spike protein and the S2 subdomain. Separately, we observed OC43-specific IgG, but not IgM, in acutely infected subjects two weeks post positive COVID-19 diagnosis, indicating that these elevated responses were not likely to result from newly-induced antibody lineages with cross-reactivity to OC43. Testing of serum samples pre- and post- SARS-CoV-2 infection reinforced the hypothesis that pre-existing clonal families were boosted by the SARS-CoV-2 infection.

By isolating antigen-specific antibodies from convalescent serum, we determined that antibodies targeting SARS-CoV-2 S-2P and S2, but not the RBD, are cross-reactive with the spike of OC43. Similarly, antibodies isolated using OC43 were cross-reactive with SARS-CoV-2 S-2P and S2 but not the RBD. These results indicate that the cross reactivity between these viral spike proteins is principally linked to the better-conserved S2 domain. Consistent with the observation that neutralizing antibodies tend to target the RBD of SARS-CoV-2<sup>36</sup>, we determined that both OC43 S-specific and SARS-CoV-2 S2-specific antibodies were non-neutralizing.

Over the course of this work, differing degrees of cross-reactivity were observed depending on whether pre-fusion-stabilized or unstabilized forms of S were used. In a comparison of naturally-infected and vaccinated subjects representing exposure to unstabilized and proline-stabilized S antigens, respectively, the immunogens starkly contrasted. The immune response that resulted from vaccination with SARS-CoV-2 S protein stabilized in the pre-fusion

conformation did not share the degree of cross-reactivity observed in those recovering from COVID-19. Reciprocally, elevated responses to stabilized OC43 were not observed in either infection or vaccination cohorts. Collectively, this data suggests both the critical importance of the conformational state of S to resulting humoral responses, but also the prevalence of epitopes that are not shared between pre and post-fusion or other conformations.

Whereas numerous studies have focused on the antibody responses elicited from vaccination towards the SARS-CoV-2 S protein and specifically the RBD, little is known about the effect previous exposure to endemic CoV may have on vaccination. However, our observations of limited boosting agree with two recent reports<sup>37,38</sup>. Evaluation of a cohort vaccinated with a non-stabilized form of S will be required to begin to elucidate whether this is a feature of the stabilization itself, the mRNA-based vaccine modality, or if some other aspect of the vaccine formulation is responsible. Finally, this evidence of cross-reactivity has implications for the design of vaccines targeting SARS-CoV-2 variants. There is a risk that subsequent antibody responses might disregard the novel epitopes in favor of those already more familiar, although it should be emphasized that cross-reactivity was not a deterrent to the development of multiple highly efficacious SARS-CoV-2 vaccines.

Limitations of this study include use of several small cohorts, some collected from distinct geographic locations, from subjects of varying age, who experienced differing disease severity, and who were not confirmed to lack a recent exposure to endemic CoV. While all natural infection cohorts showed evidence of boosting toward the endemic CoV OC43, it would be beneficial to survey boosting in cohorts that better span a range of disease severity and ages to examine whether those variables impact the observed boosting effect, and outcomes of infection. To the extent that question has been investigated, it appears that boosting of responses to endemic CoV may be associated with poorer responses to SARS-CoV-2<sup>28</sup>.

Likewise, while both vaccination cohorts showed an absence of or reduction in boosting of cross-reactive responses, whether this absence is beneficial or detrimental cannot be determined from the data presented here. While cross-reactive antibodies were non-neutralizing, neutralization is not the sole mechanism by which antibodies confer protection. Cross-reactive antibodies could interact with receptors for the Fc region of antibodies found on the surface of innate immune cells and promote protective effector function activities including antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity<sup>39-41</sup>. To this end, a subset of monoclonal antibodies isolated from SARS-CoV patients that were able to cross-react with, but not neutralize SARS-CoV-2 were able to confer protection in a mouse model<sup>42</sup>. Indeed, both passive transfer experiments of monoclonal antibodies<sup>43-47</sup> and evaluation of polyclonal

antibodies raised in the context of vaccination or infection<sup>48-50</sup> have shown that effector mechanisms contribute to antiviral activity *in vivo*. This evidence extends beyond correlative observations<sup>45,48</sup> to include mechanistic<sup>1</sup> evidence of *in vivo* contributions via Fc sequence engineering to knockout or enhance these activities<sup>44,46</sup>, as well as on the basis of depletion of effector cells<sup>46</sup>.

In sum, this study provides evidence that antibodies targeting OC43 are robustly boosted in response to SARS-CoV-2 infection but not vaccination with stabilized S, and that the S2 subdomain of the spike protein is likely responsible for triggering a recalled, IgG-dominated response. While non-neutralizing, the role of these cross-reactive antibodies in the context of infection is not yet known. Further work aimed at characterizing the effector function potential of these antibodies and understanding their role in vaccine-mediated protection could provide a more complete picture of the relative risks and benefits of this recall response relevant to vaccine design, particularly in the context of viral variants of concern.

## Methods

### *Structure Visualization and Manipulation*

The sequence alignments were performed using Geneious 2021.1.1. Sequences and coordinates for coronavirus spike proteins were retrieved from the Protein Data Bank (PDB) entries SARS-CoV-2 (PDB 6XKL), 229E (PDB 6U7H), OC43 (PDB 6OHW), NL63 (PDB 5SZS), HKU1 (PDB 5I08), and SARS-CoV-2 Closed (PDB 6X6P) (**Supplemental Table 1**). SARS-CoV-2 was structurally aligned to the other models by domain using the MatchMaker function with default parameters and visualized using Chimera version 1.15<sup>51</sup>. For structural characterization of conservation among the 60 complete genomes of the Coronaviridae suborder (<https://www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?taxid=111118>), Batch Entrez was used to find 585 associated proteins, which were then further down selected to spike proteins (N=56) and aligned using Clustal Omega. This alignment was used to render by conservation and visualized using ChimeraX version 1.2<sup>52</sup>.

### *Human Subjects*

Initial study cohorts comprised 126 adult subjects interested in donating COVID-19 convalescent plasma. All were diagnosed with SARS-CoV-2 infection by PCR-based assays of nasopharyngeal swab, met the standard eligibility criteria for blood donation and were collected in the Baltimore, MD and Washington DC area (Johns Hopkins Medical Institutions, JHMI cohort),

as previously described<sup>32</sup> and partially reported in Natarajan, et al.<sup>53</sup>, and 26 SARS-CoV-2 convalescent individuals from the Lebanon, New Hampshire area (Dartmouth-Hitchcock Medical Center, DHMC cohort) and partially reported previously in Butler, et al.<sup>31</sup> SARS-CoV-2 infection status was confirmed in all subjects by nasopharyngeal swab PCR. Plasma (JHMI) or serum (DHMC) was collected approximately one month after symptom onset or first positive PCR test.

The acute infection cohort was comprised of ten subjects under the age of thirty with mostly asymptomatic infections diagnosed by positive results of PCR swabs in twice-weekly screening tests. Serum samples were collected two weeks following a positive test result. Three subsequently infected subjects over the age of sixty with mild symptoms for which pre-pandemic serum samples had been banked were evaluated pre-infection and at two- and ten- weeks post-infection were also evaluated.

To support comparisons of natural infection and vaccination, two cohorts of pregnant women were evaluated. The first was a cohort of 38 subjects collected in Belgium who tested positive for SARS-CoV-2 in the third trimester of pregnancy. The second was a cohort of 50 subjects who were vaccinated with the Pfizer/BioNTech (BNT162) SARS-CoV-2 vaccine in the third trimester of pregnancy in Israel. Maternal serum samples were collected at time of delivery.

A final cohort of 37 healthy adults vaccinated with Pfizer/BioNTech (BNT162) (n = 35) or Moderna (n = 2) vaccines whose serum was collected approximately one week after the second vaccine dose was evaluated to confirm observations of the differing immunogenicity observed among pregnant vaccine recipients.

Negative controls included samples from 16 naïve subjects collected from the Hanover, New Hampshire area, and from 38 subjects collected pre-pandemic by a commercial vendor (BioIVT).

Human subject research was approved by the Johns Hopkins University School of Medicine's Institutional Review Board, the Dartmouth-Hitchcock Medical Center, CHU St. Pierre, Hadassah Medical Center, and BioIVT clinical site Committees for the Protection of Human Subjects as described in **Table 1**. Participants provided informed written consent. **Table 1** provides basic clinical and demographic information for each cohort.

### *Fc Array Assay*

SARS-CoV-2 antigens (**Supplemental Table 2**), including spike protein in its trimeric and subdomain forms (*i.e.*, S1, S2, RBD), endemic CoV, and the control antigens influenza hemagglutinin and tetanus toxoid were covalently coupled to Luminex Magplex magnetic microspheres by two-step carbodiimide chemistry as previously described<sup>54</sup>. Anti-isotype and

subclass primary antibodies were used to quantify the total amount of each immunoglobulin isotype in a sample before (load) and after (eluate) antigen-specific antibody purification. The load was diluted in 1x PBS by 1:100 followed by seven five-fold serial dilutions. The eluate was diluted beginning from 1:10 with six five-fold serial dilutions. Antibody isotypes and subclasses were detected using R-phycoerythrin (PE) conjugated secondary Abs as previously described<sup>55</sup>. A FlexMap 3D array instrument was then used to measure the median fluorescence intensity (MFI) of the bead sets.

### *Antigen-Specific Antibody Purification*

Human CoV antigens were covalently attached to magnetic Dynabeads (ThermoFisher, 65011) using carbodiimide chemistry and the manufacturer's instructions. Briefly, 1 nanomole of antigen was coupled to 300  $\mu$ L of beads using a solution of 10 mg/mL EDC and 10 mg/mL sulfo-NHS. Bead activation and antigen coupling took place at room temperature with end-over-end mixing for 30 minutes and overnight, respectively. Following washes, the beads were reconstituted to 150  $\mu$ L in PBS-TBN (Teknova, P0220).

The initial DHMC and JHMI cohorts were downselected to a total of 30 subjects, 15 from each cohort, representing a range of responses. Briefly, the self-reported case severities provided by the subjects of the DHMC cohort were used to select 4 mild, 5 moderate, and 6 severe subjects' samples. From the JHMI cohort, the subjects were ranked by their anti-spike titers and the five subjects closest to the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentiles were selected for purification.

In a non-binding, clear-bottom 96-well plate, 5  $\mu$ L of beads were diluted with 5  $\mu$ L of 1X PBS before adding 50  $\mu$ L of serum or plasma to the well. The plate was covered and shook at 800 rpm for 2.5 hours at room temperature. Using a magnetic base insert from a plate washer, the beads were pulled down from suspension for 1 minute before decanting the waste. The beads were washed 3 times using 100  $\mu$ L of PBS-TBN and 3 minutes of shaking for each wash. Following the third wash, the magnetic separation and decanting step was followed up by pipetting all residual buffer out of the wells while the plate sat on the magnetic base. Antibodies specific to the antigen found on the beads were eluted using 20  $\mu$ L of 1% formic acid (pH 2.9). After incubating with shaking for 10 minutes at room temperature and separating the beads, the eluate was pipetted from each well and transferred to a plate with wells containing 8  $\mu$ L of 0.5 M sodium phosphate.

### *Neutralization Assay*

Neutralization was performed using a VSV-SARS-CoV-2 pseudovirus assay as previously described<sup>31,56</sup>. Briefly, serum or plasma samples were serially diluted two-fold starting from a 1:25 dilution and incubated at 37°C for one hour with VSV-SARS-CoV-2 pseudovirus. Virus-serum/plasma mixtures were then added to pre-plated 293T-ACE2-expressing target cells in white 96-well plates at a final volume of 100 µL per well and incubated at 37°C for 24 hrs. To test for neutralization by antibody eluates, samples were first concentrated 10-fold using Amicon Ultra 0.5mL centrifugal filter devices (molecular weight cut-off of 100K Da) followed by two-fold serial dilution from 1:30, incubation with VSV-SARS-CoV-2 S pseudovirus, and addition of the mixtures to 293T-ACE2 target cells as described. Luciferase activity was measured using the Bright-Glo system and percent neutralization determined relative to control wells consisting of 293T-ACE2 cells infected with the pseudovirus alone.

### *Data Analysis*

Basic statistical data analysis and visualization of raw Fc Array data was performed using GraphPad Prism, with statistical tests described in each figure legend. Heatmaps were visualized using the 'pheatmap'<sup>57</sup> package with hierarchical cluster analysis<sup>58</sup> defined using Manhattan distance<sup>59</sup> in R version 3.6.1. Fc Array features were log transformed then scaled and centered by their standard deviation from the mean (z-score).

In order to quantify the enrichment of antigen-specific antibodies, individual features (antigen-detection pair) were plotted relative to the total immunoglobulin isotype in serum across a titration range for each sample. A generalized additive model (GAM)<sup>60</sup> with a cubic spline basis was used to fit a smoothed curve to load and eluate sample data using the 'ggplot2' package in R<sup>61</sup>. To quantify the difference between the load and eluate curves, we fit a separate GAM curve to the differences of the predicted values from the load and eluate GAM curves over total antibody as previously suggested<sup>62</sup>. We approximated the area under the difference curve (AUC) using the trapezoidal rule<sup>63,64</sup> in the 'pracma'<sup>65</sup> package in R.

### *Data Availability*

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### **Acknowledgements**

The authors acknowledge the Immune Monitoring and Flow Cytometry Resource (IMFCSR) at the Norris Cotton Cancer Center at Dartmouth supported by NCI Cancer Center Support Grant 5P30 CA023108-41. We thank all participants who enrolled and laboratory staff who helped collect and process the samples. VSV pseudovirus expression plasmids were provided by Michael Letko (Rocky Mountain Laboratories), CoV S-2P, S-6P, and RBD-Fc expression constructs were provided by Jason McLellan (University of Texas at Austin), and fusion peptide was provided by Laura Walker and Mrunal Sakharkar (Adimab). The following reagent was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor-binding domain (RBD) from SARS-Related Coronavirus 2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus, NR-52307. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, as well as extramural support from the National Institute of Allergy and Infectious Diseases (U19AI145825 to M.E.A, R01AI120938, R01AI120938S1, and R01AI128779 to A.A.R.T.), National Heart Lung and Blood Institute (K23HL151826 to E.M.B.), National Institute of General Medical Sciences (P20-GM113132 BioMT Molecular Tools Core).

### **Author Contributions**

J.L., E.M.B., A.A.R.T., A.D.R., J.N.B., D.W., T.G., A.M., and P.F.W. contributed samples and/or other materials. H.N., A.R.C., A.P.H. W.W-A., and R.I.C. collected experimental data. H.N., A.R.C., A.P.B., C.A.B., W.W-A., R.I.C., S.X., and J.A.W. performed data analysis. H.N., A.R.C., and A.P.H. drafted the manuscript. All authors reviewed and edited the manuscript. M.E.A. and P.F.W. conceived of and supervised the research.



## References


- 1 Peeri, N. C. *et al.* The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *Int J Epidemiol* **49**, 717-726, doi:10.1093/ije/dyaa033 (2020).
- 2 *Coronavirus disease (COVID-19) pandemic*, <<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>> (2021).
- 3 Reese, H. *et al.* Estimated incidence of COVID-19 illness and hospitalization - United States, February-September, 2020. *Clin Infect Dis*, doi:10.1093/cid/ciaa1780 (2020).
- 4 Kim, J. H., Skountzou, I., Compans, R. & Jacob, J. Original antigenic sin responses to influenza viruses. *J Immunol* **183**, 3294-3301, doi:10.4049/jimmunol.0900398 (2009).
- 5 Nachbagauer, R. *et al.* Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. *Nat Immunol* **18**, 464-473, doi:10.1038/ni.3684 (2017).
- 6 Francis, T., Salk, J. E. & Quilligan, J. J. Experience with Vaccination Against Influenza in the Spring of 1947: A Preliminary Report. *Am J Public Health Nations Health* **37**, 1013-1016, doi:10.2105/ajph.37.8.1013 (1947).
- 7 Fonville, J. M. *et al.* Antibody landscapes after influenza virus infection or vaccination. *Science* **346**, 996-1000, doi:10.1126/science.1256427 (2014).
- 8 Kucharski, A. J. *et al.* Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. *PLoS Biol* **13**, e1002082, doi:10.1371/journal.pbio.1002082 (2015).
- 9 Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. *Science* **354**, 722-726, doi:10.1126/science.aag1322 (2016).
- 10 Lee, J. *et al.* Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. *Cell Host & Microbe* **25**, 367-376.e365, doi:10.1016/j.chom.2019.01.010. PubMed PMID: 30795981 (2019).
- 11 Midgley, C. M. *et al.* An in-depth analysis of original antigenic sin in dengue virus infection. *J Virol* **85**, 410-421, doi:10.1128/JVI.01826-10 (2011).
- 12 Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. *Nat Rev Immunol* **20**, 633-643, doi:10.1038/s41577-020-00410-0 (2020).
- 13 Taylor, A. *et al.* Fc receptors in antibody-dependent enhancement of viral infections. *Immunol Rev* **268**, 340-364, doi:10.1111/imr.12367 (2015).
- 14 Wu, F. *et al.* Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis. *medRxiv*, 2020.2010.2008.20209114, doi:10.1101/2020.10.08.20209114 (2020).
- 15 Li, D. *et al.* In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell* **184**, 4203-4219 e4232, doi:10.1016/j.cell.2021.06.021 (2021).
- 16 Wang, Q. *et al.* Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. *ACS Infect Dis* **2**, 361-376, doi:10.1021/acsinfecdis.6b00006 (2016).
- 17 Katzelnick, L. C. *et al.* Antibody-dependent enhancement of severe dengue disease in humans. *Science* **358**, 929-932, doi:10.1126/science.aan6836 (2017).

- 18 Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol* **5**, 1185-1191, doi:10.1038/s41564-020-00789-5 (2020).
- 19 Fierz, W. & Walz, B. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. *Front Immunol* **11**, 1120, doi:10.3389/fimmu.2020.01120 (2020).
- 20 Arvin, A. M. *et al.* A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature* **584**, 353-363, doi:10.1038/s41586-020-2538-8 (2020).
- 21 Sagar, M. *et al.* Recent endemic coronavirus infection is associated with less-severe COVID-19. *J Clin Invest* **131**, doi:10.1172/JCI143380 (2021).
- 22 Aran, D., Beachler, D. C., Lanes, S. & Overhage, J. M. Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study. *J Infect* **81**, 923-930, doi:10.1016/j.jinf.2020.10.023 (2020).
- 23 Guo, L. *et al.* Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. *Emerg Microbes Infect* **10**, 664-676, doi:10.1080/22221751.2021.1905488 (2021).
- 24 Morgenlander, W. R. *et al.* Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. *J Clin Invest* **131**, doi:10.1172/JCI146927 (2021).
- 25 Wang, J., Li, D., Zhou, Q., Wiltse, A. & Zand, M. S. Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. *Front Immunol* **12**, 696370, doi:10.3389/fimmu.2021.696370 (2021).
- 26 Kaplonek, P. *et al.* Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. *bioRxiv*, doi:10.1101/2021.05.11.443609 (2021).
- 27 Ortega, N. *et al.* Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. *Nat Commun* **12**, 4740, doi:10.1038/s41467-021-24979-9 (2021).
- 28 Aydililo, T. *et al.* Immunological imprinting of the antibody response in COVID-19 patients. *Nat Commun* **12**, 3781, doi:10.1038/s41467-021-23977-1 (2021).
- 29 Yuan, M. *et al.* A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-633, doi:10.1126/science.abb7269 (2020).
- 30 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).
- 31 Butler, S. E. *et al.* Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. *Front Immunol* **11**, 618685, doi:10.3389/fimmu.2020.618685 (2020).
- 32 Klein, S. *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. *medRxiv*, doi:10.1101/2020.06.26.20139063 (2020).
- 33 Sakharkar, M. *et al.* Prolonged evolution of the human B cell response to SARS-CoV-2 infection. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abg6916 (2021).
- 34 Dugan, H. L. *et al.* Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. *Immunity* **54**, 1290-1303 e1297, doi:10.1016/j.immuni.2021.05.001 (2021).
- 35 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 36 Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* **584**, 115-119, doi:10.1038/s41586-020-2380-z (2020).


- 37 Skelly, D. T. *et al.* Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. *Nat Commun* **12**, 5061, doi:10.1038/s41467-021-25167-5 (2021).
- 38 Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell* **184**, 3936-3948 e3910, doi:10.1016/j.cell.2021.06.005 (2021).
- 39 Fox, J. M. *et al.* Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. *Sci Immunol* **4**, doi:10.1126/sciimmunol.aav5062 (2019).
- 40 Earnest, J. T. *et al.* Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. *J Exp Med* **216**, 2282-2301, doi:10.1084/jem.20190736 (2019).
- 41 Clark, M. R. IgG effector mechanisms. *Chem Immunol* **65**, 88-110 (1997).
- 42 Shiakolas, A. R. *et al.* Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. *Cell Rep Med*, 100313, doi:10.1016/j.xcrm.2021.100313 (2021).
- 43 Atyeo, C. *et al.* Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. *JCI Insight* **6**, doi:10.1172/jci.insight.143129 (2021).
- 44 Suryadevara, N. *et al.* Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. *bioRxiv*, doi:10.1101/2021.01.19.427324 (2021).
- 45 Tortorici, M. A. *et al.* Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science* **370**, 950-957, doi:10.1126/science.abe3354 (2020).
- 46 Winkler, E. S. *et al.* Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. *Cell*, doi:10.1016/j.cell.2021.02.026 (2021).
- 47 Chan, C. E. Z. *et al.* The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. *PLoS One* **16**, e0253487, doi:10.1371/journal.pone.0253487 (2021).
- 48 Alter, G. *et al.* Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. *Res Sq*, doi:10.21203/rs.3.rs-200342/v1 (2021).
- 49 Francica, J. R. *et al.* Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates. *bioRxiv*, doi:10.1101/2021.03.02.433390 (2021).
- 50 Adeniji, O. S. *et al.* COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. *mBio* **12**, doi:10.1128/mBio.00281-21 (2021).
- 51 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-1612, doi:10.1002/jcc.20084 (2004).
- 52 Goddard, T. D. *et al.* UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* **27**, 14-25, doi:10.1002/pro.3235 (2018).
- 53 Natarajan, H. *et al.* Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. *mBio* **12**, doi:10.1128/mBio.00765-21 (2021).
- 54 Brown, E. P. *et al.* High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. *Journal of immunological methods* **386**, 117-123, doi:10.1016/j.jim.2012.09.007 (2012).
- 55 Brown, E. P. *et al.* Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. *Journal of immunological methods* **443**, 33-44, doi:10.1016/j.jim.2017.01.010 (2017).

- 56 Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**, 562-569, doi:10.1038/s41564-020-0688-y (2020).
- 57 pheatmap: Pretty Heatmaps v. R package version 1.0.12 (2019).
- 58 Bridges Jr, C. C. Hierarchical cluster analysis. *Psychological reports* **18**, 851-854 (1966).
- 59 Minkowski, H. V. T. *Geometrie der zahlen*. Vol. 40 (Teubner, 1910).
- 60 Hastie, T. J. *Generalized additive models*. (2017).
- 61 Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag, 2016).
- 62 Rose, N. L., Yang, H., Turner, S. D., Simpson, G. L. An assessment of the mechanisms for the transfer of lead and mercury from atmospherically contaminated organic soils to lake sediments with particular reference to Scotland, UK. *Geochimica et Cosmochimica Acta* **82**, 113-135 (2012).
- 63 Whittaker, E. T. R., G. *The Calculus of Observations: A Treatise on Numerical Mathematics*. 4 edn, 156-158 (Dover Publications, 1967).
- 64 Poisson, S.-D. Sur le calcul numérique des intégrales définies. *Mémoires de l'Académie Royale des Sciences de l'Institut de France* **4**, 571-602 (1827).
- 65 Borchers, H. W. *pracma: Practical Numerical Math Functions*. R package version 2.3.3, (2021).


## Figures and Legends




**Graphical Abstract.** Antibody responses to SARS-CoV-2 and endemic CoV spike proteins were measured in diverse cohorts. While antibodies to SARS-CoV-2 were induced across all isotypes, only IgA and IgG responses to endemic CoV were robustly boosted, and only among naturally-infected but not vaccinated individuals. These recalled, cross-reactive responses to endemic CoV primarily recognized the better conserved S2 domain and were non-neutralizing. While other antiviral activities of broadly cross-reactive S2-specific antibodies are not known, the differing antigenicity of natural infection and vaccination with stabilized pre-fusion spike has potential implications for the breadth and level of protection afforded by each.



**Figure 1. Sequence and structural differences between the spike ectodomain of SARS-CoV-2 and endemic strains.** **A.** Sequence alignment of SARS-CoV-2 spike protein to other human coronaviruses. Consensus identity is shown on a scale from red (least conserved) to green (most conserved). Color bars are used to indicate different regions of the spike protein: N-terminal domain (NTD, blue), receptor binding domain (RBD, green) in the S1 domain and fusion peptide (FP, cyan), heptad repeat 1 (HR1, yellow), central helix (CH, orange), and connector domain (CD, purple) in the S2 domain. **B.** Structural model of the spike protein monomer colored by percent sequence conservation across deposited coronaviridae sequences shown as a ribbon model for one protomer (left) and spacefill for the spike trimer (right). **C.** Superimposed structural model of the spike protein S1 (left) and S2 (right) domains for SARS-CoV-2 (black) and OC43 (teal).




**Figure 2. SARS-CoV-2 infection is associated with elevated IgG and IgA responses to endemic CoV.** **A.** IgG responses in serum (top), nasal wash (middle), and stool (bottom) across antigens from CoV-2, OC43, and other endemic CoV S, and S1 proteins in the DHMC convalescent cohort. Samples from naïve subjects are indicated in gray, SARS-CoV-2 convalescents at one month post infection in blue, and buffer blanks in hollow circles. **B.** Volcano plot of fold change and significance (unpaired t test) of differences between antibody responses observed in convalescent subjects of the DHMC (left) and JHMI (right) cohorts one month post infection and naïve subjects in serum (top) and nasal wash (bottom). Each symbol represents an antibody response feature, with Fc domain characteristics represented by color and Fv antigen-specificity indicated by shape. Dotted horizontal line illustrates  $p = 0.05$ . Statistical significance was defined by Mann-Whitney U test.




**Figure 3: Response kinetics and isotype profiles suggest in acute and pre and post infection samples suggest recall of pre-existing, cross-reactive antibodies. A.** OC43 and CoV-2 specific IgM (orange), IgA (purple), and IgG (blue) responses in ten acutely infected subjects (color) two weeks post infection (WPI) as compared to naïve subjects (black). Statistical significance was assessed by unpaired t-test (\* $p < 0.05$ , \*\*\* $p < 0.0005$ , \*\*\*\* $p < 0.00005$ ). Fold change in means between groups are presented in inset. **B.** IgM (orange), IgA (purple), and IgG (blue) responses across CoV-2, other CoV, and control antigens in three subjects (indicated by shape) pre- (black) and post- (color) SARS-CoV-2 infection. Serum samples were taken 2 and 10 weeks post-infection (WPI).







**Figure 4. Correlative relationships between CoV-2 and OC43 specific antibody features.**  
**A.** Scatterplots of IgG responses specific to OC43 S, OC43 S2, and OC43 S-2P versus CoV-2 S2. Naïve subjects were excluded from calculations of correlative relationships. **B.** Correlations ( $R_p$ ) between IgG, IgA, and IgM specific to different stabilized SARS-CoV-2 spike and its subdomains with responses to OC43 S (maroon) and OC43 S-2P. Size and fill of symbols indicate statistical significance. Responses and relationships for naïve subjects are shown in black and convalescent donors shown in maroon (OC43 S), salmon (OC43 S2), and gray (OC43 S-2P).



**Figure 5: Poor neutralization activity of cross-reactive and S2-specific antibodies established by affinity purification.** **A.** Antigen binding profiles of IgG in unfractionated serum (load, black) and affinity-purified CoV-2 S-2P- (red, top) and OC43 S- (teal, bottom) fractions (eluate) from 30 SARS-CoV-2 convalescent subjects. Reactivity to CoV-2 S-2P, CoV-2 RBD, CoV-2 S2, OC43 S, and a control antigen (influenza HA) are reported. **B.** Antigen binding profiles of IgG (top) and IgM (bottom) in unfractionated serum (load, black) and affinity purified CoV-2 S2-specific (yellow) eluate. Reactivity to CoV-2 S2 (left) and OC43 S (right) are shown. For A-B, responses to the matched antigen (positive control) used in purification are indicated by green asterisks and to HA (negative control) antigen with red asterisks. Smoothed curves and 95% confidence intervals are shown for both eluate and load fractions. **C.** Neutralization activity of pooled elution fractions of antibodies affinity purified against CoV-2 S-2P (gray square), CoV-2 RBD (red triangle), CoV-2 S2 (yellow triangle), and OC43 S (teal circle). Error bars depict standard error of the mean across assay duplicates.



**Figure 6: Molecular cross-reactivity profiles of OC43 and SARS-CoV-specific antibody fractions across antigen specificities and Ig isotypes.** The degree of enrichment (area under the curve, AUC) of affinity purified SARS-CoV-2 RBD- (A), S-2P- (B), S2 domain- (C), or OC43 S- (D) specific antibodies of IgM (left), IgA (center), and IgG (right) isotypes across diverse CoV and control (ctl) proteins. Dotted line indicates no enrichment.



**Figure 7: Vaccination with stabilized spike does not result in robust boosting of endemic CoV responses.** IgG responses to SARS-CoV-2 (top) and OC43 (bottom) spike proteins. For each CoV strain, responses to S (left), the S2 domain (center), and stabilized S (S-2P, right) are shown. Responses in SARS-CoV-2 naïve subjects are indicated in black, SARS-CoV-2 infected subjects in light blue, and SARS-CoV-2 vaccinated (mRNA) subjects in dark blue. Pregnant subjects are indicated with triangles. Statistical significance by ANOVA with Dunnett's correction (\* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\*\* $p < 0.0001$ ). Fold changes between mean response levels in seropositive and naïve cohorts are shown below each graph.

**Table 1. Cohort characteristics.** NA indicates not applicable or available, and IQR indicates interquartile range. Partially reproduced from Natarajan, et. al, 2021.

Characteristic	DHMC Naive n=15	DHMC Convalescent n=26	JHMI Convalescent n=126	Acute n=10	Pre- and post-infection n=3	Pregnant infected n=38	Pregnant vaccinated n=50	Vaccinated n=37	Historical controls n=38
Median age (IQR), years	34 (28-52)	58 (18-77)	42 (29-53)	27 (20-30)	62 (61-64)	31 (27-35)	32 (29-35)	NA	39 (28-50)
Sex (n, %)									
Female	8 (53%)	13 (50%)	58 (46%)	3 (30%)	2 (67%)	38 (100%)	50 (100%)	17 (46%)	22 (58%)
Male	7 (47%)	13 (50%)	68 (54%)	7 (70%)	1 (33%)	0 (0%)	0 (0%)	20 (54%)	16 (42%)
Hospitalized (severity)									
No	NA	20 (77%)	114 (90.5%)	10 (100%)	3 (100%)	NA	NA	NA	NA
Yes		6 (23%)	12 (9.5%)	0 (0%)	0 (0%)				
Median days since PCR+ or symptom onset (IQR)	NA	42.5 (19-154)	43 (38-48)	11 (9-14)	12 (11-14)	49 (22-78)	NA	NA	NA
Median days since second vaccine dose (IQR)	NA	NA	NA	NA	NA	NA	20 (12-29)	8 (7-11)	NA
Location	US	US	US	US	US	Belgium	Israel	US	US
IRB	DHMC	DHMC	JHMI	DHMC	DHMC	CHU St. Pierre	Hadassah Medical Center	JHMI	BioIVT clinical sites